Although DAAs achieve sustained virologic response rates above 90%, they are expensive in both Canada and the US. A recent Canadian study examined the limitations hepatitis C patients there face in receiving reimbursement for their treatment.
One of the biggest safety risks for diabetes patients on insulin is hypoglycemia. As new treatments are developed there is a concerted effort to minimize the risk of this as part of their overall treatment picture.
Innovators have implemented pay-for-performance mandates, value-based purchasing, electronic health systems, and meticulous reporting programs. But has the quality of care or patient satisfaction improved?
In many, if not most cases, there can be a break in the chain between researchers and the doctors they are developing treatments for. When that divide does not exist it can mean more direct access for doctors and patients to the latest treatments even in the development stages.